JP2016525097A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525097A5 JP2016525097A5 JP2016524936A JP2016524936A JP2016525097A5 JP 2016525097 A5 JP2016525097 A5 JP 2016525097A5 JP 2016524936 A JP2016524936 A JP 2016524936A JP 2016524936 A JP2016524936 A JP 2016524936A JP 2016525097 A5 JP2016525097 A5 JP 2016525097A5
- Authority
- JP
- Japan
- Prior art keywords
- melanoma
- pharmaceutical composition
- composition according
- braf
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010025650 Malignant melanoma Diseases 0.000 claims 26
- 201000001441 melanoma Diseases 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 101700004551 BRAF Proteins 0.000 claims 18
- 102100004328 BRAF Human genes 0.000 claims 17
- 239000003112 inhibitor Substances 0.000 claims 17
- 230000002401 inhibitory effect Effects 0.000 claims 17
- 102000003903 Cyclin-Dependent Kinases Human genes 0.000 claims 6
- 108090000266 Cyclin-Dependent Kinases Proteins 0.000 claims 6
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 6
- 102200055464 BRAF V600E Human genes 0.000 claims 5
- 102220197820 rs121913227 Human genes 0.000 claims 4
- -1 2-chloro-4-trifluoromethylphenyl Chemical group 0.000 claims 3
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000001394 metastastic Effects 0.000 claims 3
- BFSMGDJOXZAERB-UHFFFAOYSA-N Dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N Trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 229960002465 dabrafenib Drugs 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229960004066 trametinib Drugs 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 229960003862 vemurafenib Drugs 0.000 claims 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 2
- HHCBMISMPSAZBF-UHFFFAOYSA-N 1-(3,3-dimethylbutyl)-3-[2-fluoro-4-methyl-5-[7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl]phenyl]urea Chemical compound CC1=NC2=NC(NC)=NC=C2C=C1C1=CC(NC(=O)NCCC(C)(C)C)=C(F)C=C1C HHCBMISMPSAZBF-UHFFFAOYSA-N 0.000 claims 1
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 1
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 claims 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 229950003054 Binimetinib Drugs 0.000 claims 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N Cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 claims 1
- 229960002271 Cobimetinib Drugs 0.000 claims 1
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N LGX818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)pyridine-4-carboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 claims 1
- RDSACQWTXKSHJT-NSHDSACASA-N N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 claims 1
- YZDJQTHVDDOVHR-UHFFFAOYSA-N N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 claims 1
- SUDAHWBOROXANE-VIFPVBQESA-N PD 0325901-Cl Chemical compound OC[C@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-VIFPVBQESA-N 0.000 claims 1
- 108091000081 Phosphotransferases Proteins 0.000 claims 1
- 229950002592 Pimasertib Drugs 0.000 claims 1
- 102000001253 Protein Kinases Human genes 0.000 claims 1
- 229950008933 Refametinib Drugs 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- FQUXBVQTVWLTDK-UHFFFAOYSA-N chromen-4-one;hydrochloride Chemical compound Cl.C1=CC=C2C(=O)C=COC2=C1 FQUXBVQTVWLTDK-UHFFFAOYSA-N 0.000 claims 1
- HXINDCTZKGGRDE-JPKZNVRTSA-L disodium;[3-[5-[2-[[(3R)-1-(1-methylpyrazol-3-yl)sulfonylpiperidin-3-yl]amino]pyrimidin-4-yl]imidazo[2,1-b][1,3]oxazol-6-yl]phenoxy]methyl phosphate Chemical compound [Na+].[Na+].CN1C=CC(S(=O)(=O)N2C[C@@H](CCC2)NC=2N=C(C=CN=2)C=2N3C=COC3=NC=2C=2C=C(OCOP([O-])([O-])=O)C=CC=2)=N1 HXINDCTZKGGRDE-JPKZNVRTSA-L 0.000 claims 1
- 239000003226 mitogen Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
Claims (25)
- 黒色腫を治療するための医薬組成物であって、式I
の化合物または薬学的に許容されるその塩から選択されるCDK(サイクリン依存性キナーゼ)阻害剤の治療有効量と、BRAF(セリン−トレオニンタンパク質キナーゼB−raf)阻害剤またはMEK(マイトジェン活性化タンパク質キナーゼ)阻害剤から選択される少なくとも1種の抗がん剤の治療有効量を含む、医薬組成物。 - CDK阻害剤が、式I(式中、フェニル基は、塩素およびトリフルオロメチルから選択される2つの異なる置換基で置換されている)の化合物または薬学的に許容されるその塩である、請求項1に記載の医薬組成物。
- CDK阻害剤が(+)−trans−2−(2−クロロ−4−トリフルオロメチルフェニル)−5,7−ジヒドロキシ−8−(2−ヒドロキシメチル−1−メチル−ピロリジン−3−イル)−クロメン−4−オン塩酸塩(化合物A、ボルシクリブとも呼ばれる)である、請求項2に記載の医薬組成物。
- BRAF阻害剤またはMEK阻害剤が、V600変異形態のBRAFの阻害剤である、請求項1に記載の医薬組成物。
- BRAF阻害剤が、V600E変異形態のBRAFの阻害剤である、請求項4に記載の医薬組成物。
- BRAF阻害剤が、ソラフェニブ、ベムラフェニブ、GDC−0879、ダブラフェニブ、PLX4720、BMS−908662、LGX818、PLX3603、ARQ−736、DP−4978またはRAF265から選択される、請求項1に記載の医薬組成物。
- BRAF阻害剤がベムラフェニブである、請求項4から6のいずれか一項に記載の医薬組成物。
- BRAF阻害剤がダブラフェニブである、請求項4から6のいずれか一項に記載の医薬組成物。
- MEK阻害剤が、V600EまたはV600K変異形態のBRAFの阻害剤である、請求項1または4に記載の医薬組成物。
- MEK阻害剤が、セルメチニブ、ビニメチニブ、PD−0325901、トラメチニブ、コビメチニブ、レファメチニブ、ピマセルチブ、TAK−733またはWX−554から選択される、請求項1に記載の医薬組成物。
- MEK阻害剤がトラメチニブである、請求項9または10に記載の医薬組成物。
- 前記CDK阻害剤と、BRAF阻害剤またはMEK阻害剤から選択される前記少なくとも1種の抗がん剤とが、それを必要とする対象に同時に投与される、請求項1から11のいずれか一項に記載の医薬組成物。
- 前記CDK阻害剤と、BRAF阻害剤またはMEK阻害剤から選択される前記少なくとも1種の抗がん剤とが、それを必要とする対象に逐次的に投与される、請求項1から11のいずれか一項に記載の医薬組成物。
- 黒色腫が非難治性黒色腫である、請求項1に記載の医薬組成物。
- 黒色腫が非難治性BRAF変異型黒色腫である、請求項14に記載の医薬組成物。
- 黒色腫が非難治性BRAF V600変異型黒色腫である、請求項15に記載の医薬組成物。
- 黒色腫が、非難治性BRAF V600EまたはBRAF V600K変異型黒色腫である、請求項16に記載の医薬組成物。
- 黒色腫が再発性または難治性黒色腫である、請求項1に記載の医薬組成物。
- 黒色腫が、再発性または難治性BRAF変異型黒色腫である、請求項18に記載の医薬組成物。
- 黒色腫が、再発性または難治性BRAF V600変異型黒色腫である、請求項19に記載の医薬組成物。
- 黒色腫が、再発性または難治性BRAF V600E黒色腫またはBRAF V600K変異型黒色腫である、請求項20に記載の医薬組成物。
- 黒色腫が転移性黒色腫である、請求項1に記載の医薬組成物。
- 黒色腫が転移性BRAF変異型黒色腫である、請求項22に記載の医薬組成物。
- 黒色腫が転移性BRAF V600変異型黒色腫である、請求項23に記載の医薬組成物。
- 黒色腫が転移性BRAF V600E黒色腫またはBRAF V600K変異型黒色腫である、請求項24に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361845749P | 2013-07-12 | 2013-07-12 | |
US61/845,749 | 2013-07-12 | ||
PCT/IB2014/063022 WO2015004636A1 (en) | 2013-07-12 | 2014-07-11 | A pharmaceutical combination for the treatment of melanoma |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019141995A Division JP2019206565A (ja) | 2013-07-12 | 2019-08-01 | 黒色腫の治療のための組合せ医薬 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016525097A JP2016525097A (ja) | 2016-08-22 |
JP2016525097A5 true JP2016525097A5 (ja) | 2017-08-10 |
JP6568060B2 JP6568060B2 (ja) | 2019-08-28 |
Family
ID=52279411
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016524936A Active JP6568060B2 (ja) | 2013-07-12 | 2014-07-11 | 黒色腫の治療のための組合せ医薬 |
JP2019141995A Pending JP2019206565A (ja) | 2013-07-12 | 2019-08-01 | 黒色腫の治療のための組合せ医薬 |
JP2020152028A Pending JP2021001186A (ja) | 2013-07-12 | 2020-09-10 | 黒色腫の治療のための組合せ医薬 |
JP2022026851A Pending JP2022068335A (ja) | 2013-07-12 | 2022-02-24 | 黒色腫の治療のための組合せ医薬 |
JP2023210858A Pending JP2024037891A (ja) | 2013-07-12 | 2023-12-14 | 黒色腫の治療のための組合せ医薬 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019141995A Pending JP2019206565A (ja) | 2013-07-12 | 2019-08-01 | 黒色腫の治療のための組合せ医薬 |
JP2020152028A Pending JP2021001186A (ja) | 2013-07-12 | 2020-09-10 | 黒色腫の治療のための組合せ医薬 |
JP2022026851A Pending JP2022068335A (ja) | 2013-07-12 | 2022-02-24 | 黒色腫の治療のための組合せ医薬 |
JP2023210858A Pending JP2024037891A (ja) | 2013-07-12 | 2023-12-14 | 黒色腫の治療のための組合せ医薬 |
Country Status (12)
Country | Link |
---|---|
US (4) | US11007174B2 (ja) |
EP (1) | EP3019166B1 (ja) |
JP (5) | JP6568060B2 (ja) |
CN (3) | CN105530931B (ja) |
AR (1) | AR096892A1 (ja) |
AU (1) | AU2014288857B2 (ja) |
CA (1) | CA2917742C (ja) |
DK (1) | DK3019166T3 (ja) |
ES (1) | ES2733929T3 (ja) |
IL (1) | IL243572B (ja) |
TW (2) | TWI680760B (ja) |
WO (1) | WO2015004636A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI680760B (zh) | 2013-07-12 | 2020-01-01 | 印度商皮拉馬爾企業有限公司 | 治療黑色素瘤的藥物組合 |
CN117257802A (zh) | 2015-06-05 | 2023-12-22 | 伊利诺伊大学董事会 | Pac-1联合疗法 |
EP4272735A1 (en) * | 2015-06-30 | 2023-11-08 | Genentech, Inc. | Immediate-release tablets containing a drug and processes for forming the tablets |
AU2017232496B2 (en) * | 2016-03-16 | 2022-11-24 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder |
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
US20210085663A1 (en) * | 2017-05-16 | 2021-03-25 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating cancer with atypical braf mutations |
WO2019099873A1 (en) | 2017-11-17 | 2019-05-23 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual mek signaling |
CN107827726B (zh) * | 2017-11-28 | 2020-09-15 | 辽宁中医药大学 | 马齿苋中化合物Oleracone E及其提取分离方法 |
CN108591464B (zh) * | 2018-06-28 | 2020-06-23 | 宁波奥克斯高科技有限公司 | 一种气体绝缘开关柜用密封结构 |
EP3952861A4 (en) * | 2019-04-11 | 2023-01-11 | MEI Pharma, Inc. | VORUCICLIB POLYMORPHS AND PROCESSES FOR THEIR PRODUCTION AND USE |
WO2021229439A1 (en) * | 2020-05-12 | 2021-11-18 | Novartis Ag | Therapeutic combinations comprising a craf inhibitor |
CN112168821B (zh) * | 2020-11-09 | 2022-10-14 | 中南大学湘雅医院 | 一种治疗维罗非尼耐药的黑色素瘤的联合用药物及其应用 |
IL302925A (en) * | 2020-11-19 | 2023-07-01 | Mei Pharma Inc | Treatment of KRAS mutant cancers |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN164232B (ja) | 1986-04-11 | 1989-02-04 | Hoechst India | |
USH1427H (en) | 1988-04-06 | 1995-04-04 | Briet; Phillipe | Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2 |
US5116954A (en) | 1988-04-06 | 1992-05-26 | Lipha, Lyonnaise Industrielle Pharmaceutique | Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety |
US5284856A (en) | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
US5723313A (en) | 1995-09-27 | 1998-03-03 | St. Jude Children's Research Hospital | ARF-p19, a novel regulator of the mammalian cell cycle |
US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
US6281223B1 (en) | 1999-04-13 | 2001-08-28 | Supergen, Inc. | Radioenhanced camptothecin derivative cancer treatments |
GB2361236B (en) | 2000-03-29 | 2002-04-24 | Cyclacel Ltd | Pyrimidines useful against proliferative disorders |
US6683095B2 (en) | 2000-05-03 | 2004-01-27 | Lg Life Sciences Ltd. | CDK inhibitors having 3-hydroxychromen-4-one structure |
US6699997B2 (en) | 2000-06-28 | 2004-03-02 | Teva Pharmaceutical Industries Ltd. | Carvedilol |
US7915301B2 (en) | 2002-07-08 | 2011-03-29 | Piramal Life Science Limited | Inhibitors of cyclin dependent kinases and their use |
US7271193B2 (en) * | 2002-07-08 | 2007-09-18 | Nicholas Piramal India, Ltd. | Inhibitors of cyclin-dependent kinases and their use |
US7884127B2 (en) | 2002-07-08 | 2011-02-08 | Pirimal Life Sciences Ltd. | Inhibitors of cyclin dependent kinases and their use |
TWI331034B (en) | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
AU2003276453A1 (en) | 2002-11-06 | 2004-06-07 | Cyclacel Limited | Pharmaceutical composition comprising a cdk inhibitor and gemcitabine |
GB0328180D0 (en) | 2003-12-04 | 2004-01-07 | Cyclacel Ltd | Combination |
CN1889943A (zh) | 2003-12-08 | 2007-01-03 | 美国亚利桑那大学董事会 | 协同抗癌组合物 |
EP1856083A4 (en) | 2005-03-11 | 2009-05-27 | Univ Michigan | CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC ELEMENTS OF THE BCL-2 FAMILY AND USES THEREOF |
BRPI0611863B1 (pt) * | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo |
DK2046738T3 (da) * | 2006-06-21 | 2014-08-04 | Piramal Entpr Ltd | Enantiomerisk rene flavonderivativer til behandlingen af proliferative lidelser, samt processer til deres tilberedelse |
PT2041121E (pt) | 2006-07-07 | 2011-09-12 | Piramal Life Sciences Ltd | Síntese enantiosselectiva de pirrolidinas substituídas com flavonas |
GB0706633D0 (en) | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
WO2008139271A2 (en) * | 2007-05-15 | 2008-11-20 | Piramal Life Sciences Limited | A synergistic pharmaceutical combination for the treatment of cancer |
US20100152129A1 (en) | 2008-03-31 | 2010-06-17 | Periyasamy Giridharan | Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer |
TWI461194B (zh) | 2009-05-05 | 2014-11-21 | Piramal Entpr Ltd | 吡咯啶取代黃酮作為輻射致敏劑 |
CA2790993A1 (en) | 2010-02-26 | 2011-09-01 | Piramal Enterprises Limited | Pyrrolidine substituted flavones for the treatment of inflammatory disorders |
CN101841463B (zh) * | 2010-03-05 | 2012-05-16 | 清华大学 | 基于sctp的多路径并发传输方法 |
WO2012027438A1 (en) * | 2010-08-26 | 2012-03-01 | Glaxosmithkline Llc | Pharmaceutical combination of a vegfr inhibitor and a mek inhibitor useful for treating cancer |
CN104689318A (zh) | 2010-11-19 | 2015-06-10 | 葛兰素史密斯克莱知识产权(第2号)有限公司 | 使用braf抑制剂的治疗方法 |
MX2013005661A (es) | 2010-11-19 | 2013-09-13 | Piramal Entpr Ltd | Combinacion farmaceutica de paclitaxel y un inhibidor cdk (quinasa dependiente de ciclina). |
TW201242597A (en) * | 2011-03-14 | 2012-11-01 | Piramal Life Sciences Ltd | A synergistic pharmaceutical combination for the treatment of pancreatic cancer |
TW201300105A (zh) * | 2011-05-31 | 2013-01-01 | Piramal Life Sciences Ltd | 治療頭頸鱗狀細胞癌之相乘藥物組合物 |
US20120321637A1 (en) * | 2011-06-20 | 2012-12-20 | The Board Of Regents Of The University Of Texas System | Combination cancer therapy with herv inhibition |
MX2013014950A (es) | 2011-06-24 | 2014-04-16 | Piramal Entpr Ltd | Compuestos para el tratamiento del cancer asociado con el papilomavirus humano. |
WO2013105056A1 (en) | 2012-01-13 | 2013-07-18 | Piramal Enterprises Limited | Pyrrolidine- substituted flavone derivatives for prevention or treatment of oral mucositis |
WO2014049515A1 (en) | 2012-09-25 | 2014-04-03 | Piramal Enterprises Limited | Pyrrolidine substituted flavones for treatment of renal cystic diseases |
WO2014128523A1 (en) | 2013-02-19 | 2014-08-28 | Piramal Enterprises Limited | A process for preparation of an intermediate of the pyrrolidine substituted flavones |
TWI680760B (zh) | 2013-07-12 | 2020-01-01 | 印度商皮拉馬爾企業有限公司 | 治療黑色素瘤的藥物組合 |
ES2873959T3 (es) | 2014-05-28 | 2021-11-04 | Piramal Entpr Ltd | Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer |
-
2014
- 2014-07-11 TW TW103123951A patent/TWI680760B/zh active
- 2014-07-11 CN CN201480050507.6A patent/CN105530931B/zh active Active
- 2014-07-11 DK DK14822283.9T patent/DK3019166T3/da active
- 2014-07-11 CN CN202311581824.8A patent/CN117731786A/zh active Pending
- 2014-07-11 CN CN201911007262.XA patent/CN111053768B/zh active Active
- 2014-07-11 EP EP14822283.9A patent/EP3019166B1/en active Active
- 2014-07-11 ES ES14822283T patent/ES2733929T3/es active Active
- 2014-07-11 AU AU2014288857A patent/AU2014288857B2/en active Active
- 2014-07-11 CA CA2917742A patent/CA2917742C/en active Active
- 2014-07-11 TW TW108142557A patent/TW202031253A/zh unknown
- 2014-07-11 AR ARP140102577A patent/AR096892A1/es not_active Application Discontinuation
- 2014-07-11 US US14/904,407 patent/US11007174B2/en active Active
- 2014-07-11 WO PCT/IB2014/063022 patent/WO2015004636A1/en active Application Filing
- 2014-07-11 JP JP2016524936A patent/JP6568060B2/ja active Active
-
2016
- 2016-01-11 IL IL24357216A patent/IL243572B/en active IP Right Grant
-
2018
- 2018-12-13 US US16/218,576 patent/US20190282544A1/en not_active Abandoned
-
2019
- 2019-08-01 JP JP2019141995A patent/JP2019206565A/ja active Pending
-
2020
- 2020-09-10 JP JP2020152028A patent/JP2021001186A/ja active Pending
-
2021
- 2021-02-05 US US17/168,876 patent/US11839591B2/en active Active
-
2022
- 2022-02-24 JP JP2022026851A patent/JP2022068335A/ja active Pending
-
2023
- 2023-10-30 US US18/497,653 patent/US20240165076A1/en active Pending
- 2023-12-14 JP JP2023210858A patent/JP2024037891A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016525097A5 (ja) | ||
JP2020518568A5 (ja) | ||
JP2013507415A5 (ja) | ||
JP2019510832A5 (ja) | ||
JP2016533366A5 (ja) | ||
BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
JP2017504611A5 (ja) | ||
JP2006514689A5 (ja) | 1−オキソ−2−(2,6−ジオキソピペリジン−3−イル)−4−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物 | |
JP2016508134A5 (ja) | ||
JP2018109022A5 (ja) | ||
JP2015508103A5 (ja) | ||
JP2017528475A5 (ja) | ||
JP2016520528A5 (ja) | ||
JP2016539134A5 (ja) | ||
JP2016523974A5 (ja) | ||
JP2017512791A5 (ja) | ||
JP2014521735A5 (ja) | ||
JP2015536964A5 (ja) | ||
JP2017535600A5 (ja) | ||
JP2019511526A5 (ja) | ||
JP2017533963A5 (ja) | ||
RU2017119064A (ru) | Композиции апилимода и способы его использования при лечениии меланомы | |
JP2017535601A5 (ja) | ||
JP2017511377A5 (ja) | ||
JP2019525948A5 (ja) |